SOLAIRIA Study
Back to ResearchA clinical research study to evaluate an investigational therapy for severe asthma is enrolling now.
This is a randomized, double-blind, placebo-controlled study to evaluate the investigational drug GB-0895 and see how well it works to reduce serious asthma attacks in adults and adolescents with severe asthma, when used along with other treatments.
What is the medicine in the Study?
GB-0895 is an investigational drug, a monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), which helps drive airway inflammation in asthma. In this study, it is given by injection under the skin every six months and used as an add-on to participants’ usual asthma medicines; some participants will receive placebo. It is being studied in adults and adolescents with severe, uncontrolled asthma.
You may be eligible to join this study if you:
- Are 12 to 80 years old
- Have had an asthma diagnosis for more than
2 years - Have required corticosteroids at least twice
over the last 12 months to control your asthma
Those who qualify may receive:
- Reimbursement for selected expenses
- Free study-related care
- Free study medication
If you think you are eligible and interested in taking part, please email hcl.trials@nhs.net. Study participation is voluntary by contacting us, you do not have to take part in the study.
